Bracco’s MultiHance MRI contrast agent

Bracco Diagnostics (Booth 2845), along with ACIST Medical Systems, is showcasing a portfolio of  imaging agents and delivery systems, such as MultiHance, which is indicated for intravenous use in MRI of the central nervous system in adults to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine and associated tissues.

MultiHance (gadobenate dimeglumine) is an MRI contrast agent that has nearly twice the relaxtivity of other gadolinium-based contrast agents providing a marked increase in signal-to-noise ratio in T1-weighted images, the company says. The agent demonstrates transient weak and interactions with serum proteins that causes slowing in the molecular tumbling dynamics.